GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: Fosifidancitinib is a Janus kinase (JAK) inhibitor that is claimed in Rigel Pharmaceuticals' patent WO2010085684A1 [1]. Strictly I-538 refers to the sodium salt but we represent the parent molecule in this entry. The chemical structure that was submitted to the WHO for the INN fosifidancitinib matches the structure of example I-538 (minus the sodium). Rigel declare two JAK inhibitor programmes on their pipeline webpage; one in partnership with Aclaris Therapeutics (ATI-501/ATI-502, oral and topical formulations respectively) for dermatological applications, and the second in partnership with AstraZeneca through which AZD0449 (R256) is being investigated as an inhalation asthma therapeutic. None of these investigational agents have published name to structure declarations.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| [5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-2-oxo-1,3-benzoxazol-3-yl]methyl dihydrogen phosphate |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11231 | fosifidancitinib |
Database Links ![]() |
|
| CAS Registry No. | 1237168-58-9 (source: WHO INN record) |
| GtoPdb PubChem SID | 404859084 |
| PubChem CID | 58071385 |
| Search Google for chemical match using the InChIKey | JTUBTEKGIDQZMZ-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | JTUBTEKGIDQZMZ |
| Search PubMed clinical trials | fosifidancitinib |
| Search PubMed titles | fosifidancitinib |
| Search PubMed titles/abstracts | fosifidancitinib |
| UniChem Compound Search for chemical match using the InChIKey | JTUBTEKGIDQZMZ-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | JTUBTEKGIDQZMZ-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖|
Fosifidancitinib (links to external site)
Cat. No. HY-109175 |